PRCT vs. ATRI, NNOX, INGN, BNGO, CUTR, PODD, SWAV, SOLV, TFX, and GMED
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Atrion (ATRI), Nano-X Imaging (NNOX), Inogen (INGN), Bionano Genomics (BNGO), Cutera (CUTR), Insulet (PODD), Shockwave Medical (SWAV), Solventum (SOLV), Teleflex (TFX), and Globus Medical (GMED).
Atrion (NASDAQ:ATRI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
In the previous week, Atrion had 3 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 11 mentions for Atrion and 8 mentions for PROCEPT BioRobotics. Atrion's average media sentiment score of 1.17 beat PROCEPT BioRobotics' score of 0.40 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.
Atrion received 101 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 62.22% of users gave PROCEPT BioRobotics an outperform vote while only 54.89% of users gave Atrion an outperform vote.
PROCEPT BioRobotics has a consensus price target of $61.20, indicating a potential downside of 7.83%. Given Atrion's higher probable upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Atrion.
66.2% of Atrion shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 22.8% of Atrion shares are owned by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Atrion has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.
Atrion has a net margin of 10.60% compared to Atrion's net margin of -66.12%. PROCEPT BioRobotics' return on equity of 7.75% beat Atrion's return on equity.
Atrion has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
Summary
Atrion beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PROCEPT BioRobotics Competitors List
Related Companies and Tools